Sugi Predict

Sugi Predict / Compounds / SCHEMBL873398

SCHEMBL873398

SCHEMBL873398

CC(C)(C)OC(=O)N[C@@H](C(=O)O)C(C)(C)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CTSK P43235 10/20 0.41
▸ CTSS P25774 7/20 0.41
▸ CYP2D6 P10635 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ TSHR P16473 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873787 1.00 CA1 (0.44) CA1CA2CA7MEN1GAA
SCHEMBL206502 1.00 CA1 (0.44) CA1CA2CA7MEN1GAA
SCHEMBL90052 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL83699 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL57432 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL193767 0.83 MEN1 (0.31) MEN1GAAKMT2ATSHR
SCHEMBL193766 0.83 MEN1 (0.31) MEN1GAAKMT2ATSHR
SCHEMBL23722683 0.82 CA1 (0.43) CA1CA2CA7MEN1GAA
SCHEMBL3805811 0.82 CTSK (0.44) CA1CA2CA7MEN1GAA
SCHEMBL21746358 0.82 CA1 (0.43) CA1CA2CA7MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255695-A Purification method and preparation method of intermediate of beta-lactam compound 广州艾奇西新药研究有限公司 2024-06-28 — — CN claimed
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-11-20 — — US disclosed
EP-4628488-A1 CYCLIN K DEGRADER AND USE THEREOF Adlai Nortye Biopharma Co., Ltd. (CN) 2025-10-08 — — EP disclosed
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 — — US disclosed
CN-118255695-B Purification method and preparation method of intermediate of beta-lactam compound 广州艾奇西医药科技有限公司 2025-03-14 — — CN disclosed
CN-118255695-A Purification method and preparation method of intermediate of beta-lactam compound 广州艾奇西新药研究有限公司 2024-06-28 — — CN disclosed
WO-2024125551-A1 CYCLIN K DEGRADER AND USE THEREOF 杭州阿诺生物医药科技有限公司 2024-06-20 — — WO disclosed
CN-118206535-A Cyclin K degrading agent and application thereof 杭州阿诺生物医药科技有限公司 2024-06-18 — — CN disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 — — WO disclosed
EP-2763535-B1 AZAINDOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2017-06-07 — — EP disclosed
WO-2011128381-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2011-10-20 — — WO disclosed
US-20110256128-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2011-10-20 — — US disclosed
EP-2366786-A2 Cytokine receptor modulators and uses thereof VALORISATION HSJ, Société en Commandite (CA) 2011-09-21 — — EP disclosed
US-20110144014-A1 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) 2011-06-16 — — US disclosed
US-20110136780-A1 DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-09 — — US disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 — — US disclosed
US-20100041609-A1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2010-02-18 — — US disclosed
EP-1625153-B1 ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2009-08-26 — — EP disclosed
US-20090048161-A1 Cytokine receptor modulators and uses thereof VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) 2009-02-19 — — US disclosed
US-20060094663-A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2006-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF IL17A, IL15, IL23R CA1 4798/4885CA2 4754/4885CA7 2321/4885
US-20110256128-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP17A1, CYP51A1, KLKB1 CA1 3710/4885CA2 3679/4885CA7 2823/4885
US-20110136780-A1 DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK JAK2, JAK1, JAK3 CA1 4405/4885CA2 4658/4885CA7 3851/4885
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CA1 1132/4885CA2 1566/4885CA7 1177/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D CA1 769/4885CA2 1564/4885CA7 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.